CRISPR Ther­a­peu­tics, Case­bia ink AAV deal with Stride­Bio; Puma gets an Ad­Comm date; Mer­ri­mack names new R&D chief

CRISPR Ther­a­peu­tics $CR­SP and Case­bia Ther­a­peu­tics, a joint-ven­ture es­tab­lished by CRISPR Ther­a­peu­tics and Bay­er AG, have inked a col­lab­o­ra­tion agree­ment with Stride­Bio to de­vel­op AAV vec­tors for in vi­vo gene de­liv­ery ap­pli­ca­tions. Stride­Bio’s task will be to de­vel­op “vec­tors with im­proved prop­er­ties such as tis­sue speci­fici­ty and re­duced sus­cep­ti­bil­i­ty to im­mune re­spons­es.”

→ The On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee (ODAC) will meet on May 24 to dis­cuss Puma’s $PBYI ap­pli­ca­tion for its can­cer drug ner­a­tinib.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.